


+

Substitute for form 1449A/PTO		Complete if Known	
<p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center">(Use as many sheets as necessary)</p> 		Application Number	09/933,548
		Filing Date	August 20, 2001
		First Named Inventor	Christopher William Ogden
		Group Art Unit	1645
		Examiner Name	
		Attorney Docket Number	NORT 100
Sheet 1 of 7			

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
CH		EP	0 655 926	B1	Max Planc-Gesellschaft	06-07-1995		
		PCT	WO 94/03196	A1	Max-Planck-Gesellschaft	02-17-1994	CLAIMS ONLY	
CH		PCT	WO 95/32214	A1	Canji, Inc.	11-30-1995		
CH		PCT	WO 96/02674	A1	The Johns Hopkins University School of Medicine	02-01-1996		
CH		PCT	WO 97/15686	A1	Imperial Cancer Research Technology Limited	05-01-1997		

Examine Signature	<i>Gallagher</i>	Date Considered	6/25/03
-------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known		RECEIVED SEP 24 2002 TECH CENTER 1600/2900
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/933,548	
		Filing Date	August 20, 2001	
		First Named Inventor	Christopher William Ogden	
		Group Art Unit	1645	
		Examiner Name		
Sheet 1 of 7	Attorney Docket Number	NORT 100		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T‡
461		ADAMS, et al., "Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testes," <i>Genes & Development</i> 6:1589-1607 (1992).	
466		BALAGUER, et al., "Quantification of DNA sequences obtained by polymerase chain reaction using a bioluminescent adsorbent," <i>Analytical Biochemistry</i> 195:105-110 (1991).	
466		BERNASCONI, et al., "Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins," <i>Proc Natl Acad Sci USA</i> 93:13164-69 (1996).	
466		BISCHOFF, et al., "An adventure mutant that replicates selectively in p53-deficient human tumor cells," <i>Science</i> 274:373-376 (1996).	
466		BRAWER, "Prostate Specific Antigen," <i>Acta Oncol.</i> 30:161-168 (1991).	
466		BROTHMAN, et al., "Frequency and pattern of karyotypic abnormalities in human prostate cancer," <i>Cancer Research</i> 50:3795-3803 (1990).	
466		BUSSLINGER, et al., "The role of BSAP (Pax-5) in B-cell development," <i>Current Opinion in Genetics and Development</i> 5: 595-601 (1995).	
466		Cancer Statistics: Registrations England and Wales OPCS MBI No. 22, Her Majesty's Stationery Office (1994).	
466		CANNON-ALBRIGHT & EELES, "Progress in prostate cancer," <i>Nature Genetics</i> 9:336-338 (1995).	
466		CHAMBERLAIN, et al., "Report prepared for the health technology assessment panel of the NHS execution on the diagnosis, management, treatment and costs of prostate cancer in England and Wales," <i>British Journal of Urology</i> 79(Suppl. 3):1-32 (1997).	
466		CHAN, et al., "Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study," <i>Science</i> 279:563-566 (1998).	

Examiner's Signature	<i>Cathy J. H.</i>	Date Considered	10/25/03
----------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number ‡ See attached Kinds of U.S. Patent Documents. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *** Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/933,548
		Filing Date	August 20, 2001
		First Named Inventor	Christopher William Ogden
		Group Art Unit	1645
		Examiner Name	
		Attorney Docket Number	NORT 100

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900



OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	7*
CB		COMPTON, Nucleic acid sequence-based amplification," <i>Nature</i> 350:91-92 (1991).	
CB		COTTEN, et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," <i>Proc Natl Acad Sci USA</i> 89:6094-6098 (1992).	
CB		CULVER, et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," <i>Science</i> 256:1550-1552 (1992).	
CB		CURIEL, "Adenovirus facilitation of molecular conjugate-mediated gene transfer," <i>Prog Med Virol</i> 40:1-18 (1993).	
CB		DICESARE, et al., "A high-sensitivity electrochemiluminescence-based detection system for automated PCR product quantitation," <i>BioTechniques</i> 15:152-157 (1993).	
CB		DRESSLER, et al., "Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities," <i>Nature</i> 362:665-67 (1993).	
CB		DRESSLER, et al., "Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system," <i>Development</i> 109(4): 787-795 (1990).	
CB		<u>Future Oncology</u> "Prostate Cancer-Part II: Diagnosis, Staging, Prognosis, Screening, and Novel Molecular Markers," 3(12): 1998.	
CB		GANN, et al., "A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer," <i>JAMA</i> 273: 289-294 (1995).	
CB		GAO, et al., "Diagnostic and prognostic markers for human prostate cancer," <i>The Prostate</i> 31:264-281 (1997).	
CB		GAO, et al., "High frequency of mutator phenotype in human prostatic adenocarcinoma," <i>Oncogene</i> 9:2999-3003 (1994).	

Examiner's Signature	<i>Gally Gah</i>	Date Considered	6/25/03
----------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

Complete if Known

Application Number

09/933,548

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900

Filing Date

August 20, 2001

First Named Inventor

Christopher William Ogden

Group Art Unit

1645

Examiner Name

Attorney Docket Number

NORT 100

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CF		GLEASON, "Classification of prostatic carcinomas," <i>Cancer Chemother Rep.</i> 50:125-128 (1966).	
CF		GNARRA & DRESSLER, "Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides," <i>Cancer Research</i> 55(18):4092-8 (1995).	
CF		JACOBS, et al., "Thermal stability of oligonucleotide duplexes is sequence independent in tetraalkylammonium application to identifying recombinant DNA clones," <i>Nucl. Acids Res.</i> 16:4367 (1988).	
CF		KHOUBEHI, et al., "The expression of the PAX2 in human prostate cancer," <i>Am J Human Genetics</i> 65(Suppl. 4):A132 (1999).	
CF		KHOUBEHI, et al., "Expression of the developmental and oncogenic PAX2 gene in human prostate cancer," <i>J Urology</i> 165(6.1): 2115-2120.	
CF		KOONTZ, et al., "Mitomycin for patients who have failed on thiotepa," <i>Urology</i> 26(4 Suppl.):30-31 (1985).	
CF		KURIYAMA, et al., "A Potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," <i>Cell Structure and Function</i> 16:503-510 (1991).	
CF		LEDLEY, "Nonviral gene therapy: The promise of genes as pharmaceutical products," <i>Human Gene Therapy</i> 6:1129-1144 (1995).	
CF		LI, et al., "PTEN, a putative Protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer," <i>Science</i> 275:1943-1947 (1997).	
CF		LUNDWALL, "Characterization of the gene for prostate-specific antigen, a human glandular kallikrein," <i>Biochem. Biophys. Res. Comm.</i> 161(3): 1151-1159 (1989).	
CF		MARTIN & PAPAHDJOPOULOS, et al., "Irreversible coupling of immunoglobulin fragments to preformed vesicles," <i>J Biol Chem</i> 257:286-88 (1982).	

Examiner's Signature	<i>Colin Cahn</i>	Date Considered	6/25/03
----------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 		Application Number	09/933,548
		Filing Date	August 20, 2001
		First Named Inventor	Christopher William Ogden
		Group Art Unit	1645
		Examiner Name	
Sheet 1 of 7	Attorney Docket Number	NORT 100	

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CH		MASSENKEIL, et al., "P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer," <i>Anticancer Res.</i> 14(6B): 2785-2790 (1994).	
CH		MAULBECKER & GRUSS, "The oncogenic potential of Pax genes," <i>EMBO Journal</i> 12(6): 2361-2367 (1993).	
CH		MICHAEL, et al., "Addition of a short peptide ligand to the adenovirus fiber protein," <i>Gene Therapy</i> 2:660-668 (1982).	
CH		MILLER & VILE, "Targeted vectors for gene therapy," <i>FASEB Journal</i> 9(2): 190-199 (1995).	
CH		Mortality Statistics: Cause. England and Wales. OPCS DH2 19, Her Majesty's Stationery Office, 1993.	
CH		NASSANDER, et al., "In vivo targeting of OV-TL 3 immunoliposomes to Ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice," <i>Cancer Research</i> 52:646-653 (1992).	
CH		NIHEI, et al., "Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10," <i>Genes, Chromosomes & Cancer</i> 14(2): 112-119 (1995).	
CH		PHELPS & DRESSLER, "Aberrant expression of Pax-2 in Danforth's short tail (Sd) mice," <i>Developmental Biology</i> 157(1): 251-258 (1993).	
CH		POGREBNIK, et al., "Targeted phototherapy with sensitizer-monoclonal antibody conjugate and light," <i>Surgical Oncology</i> 2(1): 31-42, 1993.	
CH		RIEGMAN, et al., "Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene," <i>Biochem Biophys. Res. Comm.</i> 159(1): 95-102 (1989).	
CH		RYAN, et al., "Repression of Pax-2 by WT1 during normal kidney development," <i>Development</i> 121: 867-875 (1995).	

Examiner's Signature		Date Considered	6/25/03
----------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

SEP 23 2002



(Use as many sheets as necessary)

Complete If Known

Application Number	09/933,548
Filing Date	August 20, 2001
First Named Inventor	Christopher William Ogden
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	NORT 100

Sheet 6 of 7

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T‡
4H		SAIKI, et al., "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase," <i>Science</i> 239:487-491 (1988).	
4B		SANYANUSIN, et al., "Fenomic structure of the human PAX2 gene," <i>Genomics</i> 35(1): 258-261 (1996).	
4B		SCHAFER, et al., "Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes," <i>Nuc. Acids Res.</i> 22(22): 4574-4582 (1994).	
4B		SMITH & CATALONA, "Interexaminer variability of digital rectal examination in detecting prostate cancer," <i>Urology</i> 45(1): 70-74 (1995).	
4B		STECK, et al., "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers," <i>Nature Genetics</i> 15: 356-363 (1997).	
4B		STUART & GRUSS, "PAX genes: What's new in developmental biology and cancer?" <i>Human Mol. Gen.</i> 4: 1717-1720 (1995).	
4B		STUART, et al., "Loss of p53 function through PAX-mediated transcriptional repression," <i>EMBO Journal</i> 14: 5638-5645 (1995).	
4B		STUART, et al., "Mammalian PAX genes," <i>Annu Rev. Genet.</i> 27: 219-236 (1993).	
4B		STUART, et al., "PAX and HOX in Neoplasia," <i>Adv. Genet.</i> 33: 255-274 (1995).	
4B		WAGNER, et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells," <i>Proc. Nat. Acad. Sci. USA</i> 87: 3410-3414 (1990).	
4B		WALKER, et al., "Strand displacement amplification -- an isothermal, in vitro DNA amplification technique," <i>Nuc. Acids. Res.</i> 20(7): 1691-1696 (1992).	

Examiner's Signature		Date Considered	6/25/03
----------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number ‡ See attached Kinds of U.S. Patent Documents. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *** Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

